Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"HER2 Antibody"”.
-
INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY
… human epidermal growth factor receptor-2 (HER2) specifically in breast cancer. Poly (D, L-lactide-co-glycolide) (PLGA) polymer, which is approved by FDA, was used to form nanoparticles (NPs) encapsulating docetaxel (DOC) as chemotherapy. HER2 antibody moieties, either whole IgG (TrAb) or …
-
Self-assembled Polymeric Nanoparticles for Targeted Delivery of Anticancer Drugs
… epidermal growth factor receptor 2 (anti-HER2) antibodies to the self-assembled nanoparticles through Diels-Alder (DA) chemistry. This new coupling methodology was demonstrated to be relatively rapid, highly efficient and specific under mild conditions. In vitro studies showed that the …
-
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
… and trastuzumab emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive biomarkers for ADCs, …
-
NANOTECHNOLOGICAL APPROACHES FOR CANCER DIAGNOSIS, TREATMENT AND MANAGEMENT: IMPLEMENTATION OF FERRITIN PROTEIN NANOPARTICLES FOR TUMOR TARGETING
… HFn nanocages conjugated to the monoclonal anti-HER2 antibody trastuzumab (TZ). By exploiting the ability of HFn to cross the blood brain barrier (BBB), we achieved the delivery of TZ as a prophylactic treatment to tackle brain metastasis in HER2-positive advanced breast cancer.
-
Assembly, characterization and evaluation of a 3rd generation nanoparticle based drug carrier for metastatic breast cancer treatment
… high drug loading and controlled release. Anti-Her2 antibody or Herceptin® was grafted onto the surface of the liposome for a higher affinity to the Her2 overexpressing breast cancer cells. Firstly, the conjugation of protein to the surface of liposome and PEGylated liposomes were investigated. …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… rates. Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of BC. HER2 overexpression is also observed in other cancers such as gastric/gastroesophageal, ovarian, lung, prostate, bladder, colon and head and neck. HER2-positive BC is characterized by aggressive disease and …